List of Zecuity drug patents
Zecuity is owned by Teva Branded Pharm.
Zecuity contains Sumatriptan Succinate.
Zecuity has a total of 10 drug patents out of which 0 drug patents have expired.
Zecuity was authorised for market use on 17 January, 2013.
Zecuity is available in system;iontophoresis dosage forms.
Zecuity can be used as method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation.
The generics of Zecuity are possible to be released after 08 October, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6745071 | TEVA BRANDED PHARM | Iontophoretic drug delivery system |
Feb, 2023
(15 days from now) | |
| US8155737 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(4 years from now) | |
| US8470853 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(4 years from now) | |
| US7973058 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Apr, 2027
(4 years from now) | |
| US9427578 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(4 years from now) | |
| US8597272 | TEVA BRANDED PHARM | Pharmacokinetics of iontophoretic sumatriptan administration |
Apr, 2027
(4 years from now) | |
| US9272137 | TEVA BRANDED PHARM | Transdermal methods and systems for the delivery of anti-migraine compounds |
Sep, 2027
(4 years from now) | |
| US8366600 | TEVA BRANDED PHARM | Polyamine enhanced formulations for triptan compound iontophoresis |
Apr, 2029
(6 years from now) | |
| US8983594 | TEVA BRANDED PHARM | Electronic control of drug delivery system |
Nov, 2030
(7 years from now) | |
| US9327114 | TEVA BRANDED PHARM | User-activated self-contained co-packaged iontophoretic drug delivery system |
Oct, 2032
(9 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 17 January, 2013
Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof, using a flowable hydrogel formulation
Dosage: SYSTEM;IONTOPHORESIS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic